ClinicalTrials.gg
Not yet recruitingNCT07063407Updated Jul 14, 2025

Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer

A Phase 1 interventional study of HS-20093 in combination with Adebrelimab in Extensive Stage Small Cell Lung Cancer (ES-SCLC), sponsored by Shanghai Hansoh Biomedical Co., Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Shanghai Hansoh Biomedical Co., Ltd (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing adebrelimab in Small Cell Lung Carcinoma — 21 open to participants now, 23 under way, 2 of them phase 3. adebrelimab · Small Cell Lung Carcinoma.

Planned enrollment
11th of 25
50 · median 47
Started
2025
with 6 others
Phase 1
3 of 25
2 open now
Primary completion
2026-04
later than 3 of 22 live
Registered
19th of 25
by date

Among the 25 studies testing adebrelimab in Small Cell Lung Carcinoma, this one is the 11th largest by planned enrollment, is one of 7 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 3 of the 22 other live ones, and was the 19th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

21 of the 25 studies testing adebrelimab in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing adebrelimab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

Read the detailed description

This is a multicenter, open-label Phase I clinical study to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with ES-SCLC. Patients with ES-SCLC without disease progression after receiving first-line standard induction therapy (Platinum + Etoposide +PD- (L) 1 inhibitor combination therapy) will receive maintenance therapy of HS-20093 in combination with Adebrelimab. Patients will continue treatment until disease progression or other criteria for termination of treatment are met.

03

Conditions studied

  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:

  1. Men or women aged more than or equal to (≥) 18 years.
  2. diagnosed as ES-SCLC.
  3. Without disease progression after receiving standard induction therapy (Platinum + Etoposide +PD- (L) 1 inhibitor combination therapy).
  4. (ECOG) performance status: 0\~1.
  5. Estimated >12 weeks.
  6. Adequate bone marrow reserve or serious organ dysfunction
  7. Reproductive-age women agree to use adequate and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.
  8. Females must have evidence of non-.
  9. Signed and dated Form.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled pleural effusion or ascites or pericardial effusion.
  2. Known and untreated, or active central nervous system .
  3. Active diseases or active infectious disease
  4. Known to have interstitial pneumonia or immune pneumonia
  5. History of severe allergic reaction, serious transfusion reactions or Allergy to any component of HS-20093
  6. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator.
  7. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator.
  8. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.
  9. History of neuropathy or mental disorders, including epilepsy and dementia.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    HS-20093 and Adebrelimab

    Drug: HS-20093 in combination with Adebrelimab

Interventions

  • DrugHS-20093 in combination with Adebrelimab

    Drug pages: Risvutatug rezetecan · Adebrelimab

    HS-20093 in combination with Adebrelimab will be administered intravenously every 3 weeks until disease progression or other criteria for termination of treatment are met.

06

What researchers measure

Primary outcomes

  1. Pogression-free survival (PFS) determined by investigators according to RECIST 1.1

    PFS is defined as the time from date of first dose until the documentation of objective PD or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.

    Time frame: up to approximately 24 months

Secondary outcomes

  1. Incidence of adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant administered an investigational product, which may present with symptoms, signs, disease, or laboratory abnormalities, but do not necessarily have a causality with the investigational product.

    Time frame: From the first dose through 90 days post end of treatment

  2. Objective response rate (ORR) assessed by investigator

    ORR is defined as the percentage of patients with a CR or PR that is confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1

    Time frame: up to approximately 24 months

  3. Disease Control Rate (DCR)

    Disease control is defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 5 weeks).

    Time frame: up to approximately 24 months.

  4. Duration of response (DOR)

    Duration of response assessed by RECIST 1.1. Duration of response is defined as the time from when the criteria for CR or PR were first met to the occurrence of an objective disease progression (PD) or death.

    Time frame: up to approximately 24 months.

  5. Overall survival (OS)

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: up to approximately 24 months.

  6. Observed maximum plasma concentration (Cmax) of HS-20093

    Cmax of HS-20093

    Time frame: up to approximately 24 months.

  7. Area Under the Plasma Concentration-Time Curve (AUC) of HS-20093

    AUC of HS-20093

    Time frame: up to approximately 24 months.

  8. Percentage of participants with antibodies to HS-20093 in serum

    Serum samples were collected for the determination of anti-drug antibody (ADA) at designated time points

    Time frame: up to approximately 24 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Apr 2026, 8 months later.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 8 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 14, 2025
StartEst.
Jul 31, 2025
Primary completionEst.
Apr 30, 2026
CompletionEst.
May 31, 2027
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07063407
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jul 31, 2025 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jul 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risvutatug rezetecan · Adebrelimab

Start the discussion